Cargando…

Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor

We administered recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) to four patients with myelodysplastic syndrome (MDS) and three patients with non‐MDS (two malignant lymphoma and one lung cancer) as a part of a phase II trial and analyzed the effects of rhG‐CSF on the neoplastic cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohyashiki, Kazuma, Ohyashiki, Junko H., Toyama, Keisuke, Takaku, Fumimaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1989
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917852/ https://www.ncbi.nlm.nih.gov/pubmed/2480943 http://dx.doi.org/10.1111/j.1349-7006.1989.tb01725.x

Ejemplares similares

MORPHOLOGIC CHANGES OF NEUTROPHILS IN MYELODYSPLASTIC SYNDROME TREATED WITH RECOMBINANT HUMAN GRANULOCYTE COLONY‐STIMULATING FACTOR
por: Toyama, Keisuke, et al.
Publicado: (1988)

Non‐radioisotopic and Semi‐quantitative Procedure for Terminal Repeat Amplification Protocol
por: Ohyashiki, Junko H., et al.
Publicado: (1996)

Characteristics of Granulocyte‐Macrophage Colony Formation in Chronic Myelomonocytic Leukemia: A Comparative Study with Other Myelodysplastic and Myeloproliferative Disorders
por: Yuo, Akira, et al.
Publicado: (1990)

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes
por: Ohyashiki, Kazuma, et al.
Publicado: (1990)

Binding Properties and Proliferative Effects of Human Recombinant Granulocyte‐Macrophage Colony‐stimulating Factor in Primary Leukemia and Lymphoma
por: Piao, Yun‐Feng, et al.
Publicado: (1989)

Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis
por: Gladkova, Nina, et al.
Publicado: (2020)

Effects of the in vivo Administration of Recombinant Human Granulocyte Colony‐stimulating Factor Following Cytotoxic Chemotherapy on Granulocytic Precursors in Patients with Malignant Lymphoma
por: Ema, Hideo, et al.
Publicado: (1989)

Age-related decrease of miRNA-92a levels in human CD8(+ )T-cells correlates with a reduction of naïve T lymphocytes
por: Ohyashiki, Michiyo, et al.
Publicado: (2011)

A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome
por: Asano, Michiyo, et al.
Publicado: (2019)

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells
por: Ohyashiki, Junko H, et al.
Publicado: (2008)

Induction of Tumor Necrosis Factor in Mice by Recombinant Human Macrophage Colony‐stimulating Factor
por: Sakurai, Takuma, et al.
Publicado: (1994)

Transcriptional profiling of Epstein–Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection
por: Zhang, Y, et al.
Publicado: (2006)

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
por: Ohyashiki, Junko H, et al.
Publicado: (2012)

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells
por: Imanishi, Satoshi, et al.
Publicado: (2018)

Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients
por: Tanaka, Masami, et al.
Publicado: (2009)

Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma
por: Ohyashiki, Kazuma, et al.
Publicado: (2011)

Role of Granulocyte-Macrophage Colony-Stimulating Factor in Acute Myeloid Leukemia/Myelodysplastic Syndromes
por: Kassem, Neemat M., et al.
Publicado: (2017)

Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a
por: Ohyashiki, Junko H, et al.
Publicado: (2010)

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
por: Ohyashiki, Junko H, et al.
Publicado: (2014)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells
por: Hamamura, R S, et al.
Publicado: (2007)

Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation
por: Yoshizawa, Seiichiro, et al.
Publicado: (2018)

Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15
por: Nishi, Hirotaka, et al.
Publicado: (2023)

Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells
por: Ohyashiki, J H, et al.
Publicado: (2005)

Mutations of N‐ras Oncogene in Myelodysplastic Syndromes and Lcukemias Detected by Polymerase Chain Reaction
por: Mano, Hiroyuki, et al.
Publicado: (1989)

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
por: Ohyashiki, Kazuma, et al.
Publicado: (2016)

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017)

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
por: Yoshimoto, Takayuki, et al.
Publicado: (2014)

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
por: Veldhuis, G. J., et al.
Publicado: (1997)

Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates
Publicado: (1987)

Severe Drug-Induced Agranulocytosis Successfully Treated with Recombinant Human Granulocyte Colony-Stimulating Factor
por: Kubota, Yohei, et al.
Publicado: (2018)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats
por: Papalois, Apostolos E., et al.
Publicado: (2019)

Enhancement of the Antibody‐dependent Tumoricidal Activity of Human Monocytes by Human Monocytic Colony‐stimulating Factor
por: Suzu, Shinya, et al.
Publicado: (1990)

Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor
por: Nautiyal, Kirtan, et al.
Publicado: (2014)

Erratum to “Severe Drug-Induced Agranulocytosis Successfully Treated with Recombinant Human Granulocyte Colony-Stimulating Factor”
por: Kubota, Yohei, et al.
Publicado: (2018)

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.
por: Bronchud, M. H., et al.
Publicado: (1988)

Development of Wolffia arrhiza as a Producer for Recombinant Human Granulocyte Colony-Stimulating Factor
por: Khvatkov, Pavel, et al.
Publicado: (2018)

An open-label pilot study of recombinant granulocyte-colony stimulating factor in Friedreich’s ataxia
por: Kemp, Kevin C., et al.
Publicado: (2022)

Clinical, hematological, and cytogenetic profile of adult myelodysplastic syndrome in a tertiary care center
por: Narayanan, Santhosh
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nd8i0sisb34ua0anid7lfb8laq